Preliminary safety and efficacy report of a randomized trial of alemtuzumab vs chlorambucil as front-line therapy in 297 patients with progressive B-cell chronic lymphocytic leukemia.

被引：2
|
作者：
Hillmen, P
Skotnicki, AB
Robak, T
Mayer, J
Jaksic, B
Vukovic, V
Weitman, S
机构：
[1] Leeds Gen Infirm, PL-90131 Wakefield, England
[2] Jagiellonian Univ, Krakow, Poland
[3] Med Univ Lodz, Lodz, Poland
[4] Univ Hosp Brno, Brno, Czech Republic
[5] Univ Zagreb, Clin Hosp Merkur, Zagreb, Croatia
[6] Ilex Pharmaceut LP, San Antonio, TX USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
10.1182/blood.V104.11.2505.2505
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2505
引用
收藏
页码：687A / 687A
页数：1
相关论文
共 50 条
  • [21] Impact of prognostic factors on outcome in a phase III study comparing alemtuzumab to chlorambucil as first-line therapy for B-cell chronic lymphocytic leukemia (BCLL)
    Mayer, J.
    Robak, T.
    Skotnicki, A.
    Jaksic, B.
    Dmoszynska, A.
    Sirard, C.
    Hillmen, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [22] Clinical efficacy and safety of combined thalidomide and fludarabine therapy in B-cell chronic lymphocytic leukemia patients.
    Dmoszynska, Anna
    Giannopoulos, Krzysztof
    Kowal, Malgorzata
    Podhorecka, Monika
    Wlasiuk, Paulina
    Bojarska-Junak, Agnieszka
    Trzesniewska, Wioletta
    Rolinski, Jacek
    BLOOD, 2006, 108 (11) : 332B - 332B
  • [23] Cytogenetic abnormalities and associated efficacy from a phase III study comparing alemtuzumab vs. chlorambucilas first line therapy for B-cell chronic lymphocytic leukemia
    Robak, T.
    Skotnicki, A.
    Dmoszynska, A.
    Hebert, J.
    Wang, Y.
    Belkaci, M.
    Sirard, C.
    Mayer, J.
    Hillmen, P.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 46 - 46
  • [24] Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification
    Laurenti, Luca
    Innocenti, Idanna
    Autore, Francesco
    Ciolli, Stefania
    Mauro, Francesca Romana
    Mannina, Donato
    Del Poeta, Giovanni
    D'Arena, Giovanni
    Massaia, Massimo
    Coscia, Marta
    Molica, Stefano
    Pozzato, Gabriele
    Efremov, Dimitar G.
    Vannata, Barbara
    Marasca, Roberto
    Galieni, Pietro
    Cuneo, Antonio
    Orlando, Sonia
    Piciocchi, Alfonso
    Boncompagni, Riccardo
    Vincelli, Donatella
    Liberati, Anna Marina
    Russo, Filomena
    Foa, Robin
    HAEMATOLOGICA, 2017, 102 (09) : E352 - E355
  • [25] Bendamustine is an effective and well tolerated therapy in heavily pretreated patients with B-cell chronic lymphocytic leukemia.
    Henze, L
    Aivado, M
    Burger, J
    Kuendgen, A
    Strupp, C
    Schulte, K
    Kronenwett, R
    Finke, J
    Haas, R
    BLOOD, 2002, 100 (11) : 388A - 388A
  • [26] Efficacy and Safety Of Bendamustine In Combination With Rituximab For Elderly Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia. A Retrospective Multicenter Study
    Laurenti, Luca
    Vannata, Barbara
    Innocenti, Idanna
    Autore, Francesco
    Ghio, Francesco
    Cecconi, Nadia
    Pitini, Vincenzo
    Mondello, Patrizia
    Lanza Cariccio, Maria Rosa
    Gozzetti, Alessandro
    D'Arena, Giovanni
    Murru, Roberta
    Piccirillo, Nicola
    Leone, Giuseppe
    Sica, Simona
    BLOOD, 2013, 122 (21)
  • [27] Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia
    Laurenti, L.
    Tarnani, M.
    Efremov, D. G.
    Fiorini, A.
    De Matteis, S.
    Chiusolo, P.
    De Padua, L.
    Innocenti, I.
    Sica, S.
    Leone, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 367 - 368
  • [28] Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia
    Laurenti, L.
    Tarnani, M.
    Efremov, D. G.
    Chiusolo, P.
    De Padua, L.
    Sica, S.
    Leone, G.
    LEUKEMIA, 2007, 21 (08) : 1819 - 1821
  • [29] Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia
    L Laurenti
    M Tarnani
    D G Efremov
    P Chiusolo
    L De Padua
    S Sica
    G Leone
    Leukemia, 2007, 21 : 1819 - 1821
  • [30] Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial
    Robak, T
    Blonski, JZ
    Kasznicki, M
    Blasinska-Morawiec, M
    Krykowski, E
    Dmoszynska, A
    Mrugala-Spiewak, H
    Skotnicki, AB
    Nowak, W
    Konopka, L
    Ceglarek, B
    Maj, S
    Dwilewicz-Trojaczek, J
    Heilmann, A
    Urasinski, I
    Zdziarska, B
    Kotlarek-Haus, S
    Potoczek, S
    Grieb, P
    BLOOD, 2000, 96 (08) : 2723 - 2729
12345